18.11.2013 • News • Dede Willams • joint venture • Mergers & Acquisitions (M&A)

Solvay in Fluoropolymers JV With Shanghai Producer

Belgian chemical group Solvay has licensed its technology for fluorinated polymers to China's Shanghai 3F New Material Co. as part of an 80:20 joint venture agreement covering supply of high-performance fluorinated polymers to the Asian market.

Shanghai 3F New Material Co. will have the 80% majority in the joint company and will contribute production facilities for the monomer and polymers. It will supply Solvay's adjacent specialty polymers production unit for the strategic raw materials 142b and HFP, enriching the fluoropolymer mix for applications in automotive, photovoltaics, Li-ion batteries, membranes and oil & gas applications.

Production facilities of both companies are currently under construction at Changsu, China. The joint venture's TFE/PTFE plant is due to be completed in Q1 2014. Solvay's new fluoropolymer plant is due to be completed in stages up to the end of 2015.

 

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Top-Feature

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.